SAN DIEGO, November 10, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster presentation of preclinical data for its lead product candidate, eFT508, that defines its immunological mechanism of acti...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced positive topline results from a Phase 2 proof-of-concept study of ATR-101 in classic congenital adrenal hyperplasia (CAH...

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies, today a...

-- Expands technology and global footprint with acquisition of Humabs BioMed SA

-- Accesses clinical and preclinical stage assets from Alnylam, Visterra

-- Total financing to date exceeds $500 million

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Al...

Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has initiated dosing in a Phase 2 clinical study...

This quiet biotech is looking for curative therapies and new vaccines for a host of infectious diseases with an experienced biopharma executive team.

CEO:  George Scangos
Based:  San Francisco
Founded: 2017
Clinical focus: Infectious diseases

The scoop: When George Scangos stepped down as CEO of Biogen in l...

Emeryville, CA, September 26, 2017 – Gritstone Oncology, a next-generation personalized cancer immunotherapy company, has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.

Founded in O...

BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one of the “up-and-coming privately-held biotech companies expected to make big waves in the industry.” The annual Fierce 15 list celebrates the spirit of being “fierce” –...

Boston-based Indigo announced Tuesday the first closing of $156 million in its Series D financing, doubling the company’s total capital raised to over $300 million. 

Since the latest round now has Indigo valued at $1.4 billion, according to a company spokesperson, the agriculture startup is officially Bost...

Proceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of Personalized Cancer Immunotherapies
 

Lead Program Expected to Enter Clinical Trials in Mid-2018
 

Personalized Immunotherapy Manufacturing Facility Under Construction and will Provi...